Ibrutinib is a new targeted therapy for the treatment of Alzheimer’s disease. This drug, in combination with other drugs, seems to be effective in treating the symptoms of the disease.
Based on results of a pivotal study comparing FCR to an alternative rituximab-based therapy, patients receiving ibrutinib at https://www.aasraw.com/products/ibrutinib/ rituximab treatment had a remarkable two-thirds decrease in the risk of Alzheimer’s disease progression relative to patients receiving usual care.
Overall survival was also improved for patients getting ibrutinib treatment compared to those receiving usual care. However, the drug has not yet been approved by the FDA for this use.
Ibrutinib is a novel anticancer agent and thus its mechanism of action is still being studied extensively. It has been used in the treatment of various cancers including breast, prostate, ovarian, cervical, kidney, pancreatic, Hodgkin’s disease and metastatic colorectal cancer.
It is also applied to treat various non-cancerous tumors and to prevent cancer in general. The mechanism of action is not clearly defined; however, it may activate the immune system or it may stimulate the cell cycle.
In addition to treating patients with Alzheimer’s disease, Ibrutinib is also effective in the management of other forms of cancer including lung, liver, bladder, pancreas, prostate, throat, ovary and kidney cancers. In the early stages of the disease, it can also be used in combination with radiation therapy and/or chemotherapy to improve survival.
Ibrutinib is an exceptional compound due to its intracellular antioxidant activity. This property is believed to be the basis of its efficacy in the management of various types of cancer. It has been found to have significant cytotoxic, antimicrobial and anti-inflammatory properties.
Ibrutinib is generally administered once a day in combination with a regimen of highly potent non-cancerous anti-inflammatory agents and oxygenating agents. Patients must not exceed the maximum dosage recommended for healthy adults. Irregular heart rhythms, skin rash, mild dehydration and allergic reactions are the most common effects. These are normally reversible.
In phase I clinical trials, patients treated with Ibrutinib were more likely to achieve complete survival (vs. survive) when compared with placebo recipients. The improvement was especially striking in patients who had poor responses to Ibrutinib.
At the conclusion of the study, the majority of participants achieved either a treatment record that was more satisfactory or a clinically cure response. At this point, it is not clear which Ibrutinib is a more effective, and thus, the optimal, targeted drug therapy.
Ibrutinib like AZD 3759 is a targeted therapy to treat B lymphomas, small cell lung cancers (SCLC) and permanently infected grafts. Ibrutinib is a promising therapy but still needs to be developed further to help clinicians target the disease precisely and achieve successful outcomes.
In the interim, existing treatments combined with Ibrutinib may help improve survival rates and extend life for many patients. This is why we consider Ibrutinib a “first-line” therapy in our clinical practice.